The deal aims to strengthen Dalton's offerings within the outsourcing sector, which already includes cGMP manufacturing and sterile filling services to clients at Phase I, II or III of the regulatory process.
The formation of Dalton Medicinal Chemistry Partners is the result of a joint venture with Dr. Judd Berman, a scientist who has held positions at Merrell Dow, Glaxo, GlaxoWellcome, GSK and most recently Affinium Pharmaceuticals.
"Judd's broad experience and abilities in drug discovery using medicinal chemistry, as well as his track record in identification and optimisation of high quality lead compounds, combined with Dalton's 20 year history of success in drug development, creates a powerful combination," said Peter Pekos, President and CEO of Dalton Pharma Services.
"Taking full advantage of our state of the art facilities, this new venture makes significant additional scientific and managerial expertise available to our clients and augments Dalton's ability to identify and deliver promising small molecules quickly for our partners' programs," added Pekos.
Dalton Pharma Services is a contract pharmaceutical manufacturer that supplies chemistry and analytical services to the biotechnology and pharmaceutical industries in the areas of medicinal chemistry, fine chemical manufacture, custom peptides and antisense oligo production.
Dalton's services include producing active pharmaceutical ingredients (API), at the gram or kilogram scale.
Dalton can also carry out sterile fills to produce batches of finished drug product in vials or syringes, either aseptically filled or terminally sterilised, under fully validated conditions.
In addition, Dalton's analytical chemistry laboratory offers method development, validation and ICH stability programs to its clients.